Articles from Global Alzheimer’s Platform Foundation®

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data

Tampa, Fla., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Axiom Brain Health (Axiom) and the Global Alzheimer’s Platform Foundation® (GAP) celebrated the next chapter in neurodegenerative research at the launch of the newly renovated site on Thursday, January 23. The expansion of the research facility accommodates the growing need for more research of Alzheimer’s, Multiple Sclerosis, Parkinson’s, and other life-threatening neurodegenerative diseases. 

Washington D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities in order to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias.  

Lilly joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias across diverse populations

Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study

Partnership to Cultivate Best-In Class Clinical Research Services for Alzheimer’s disease and related dementias

The results of the Bio-Hermes study appear in Alzheimer's & Dementia showing how new Alzheimer’s detecting blood tests perform across a broad range of races and ethnicities for the first time.